POINT Solid Tumor Next-Generation Sequencing Panel
Synonyms |
|
Cerner Name |
|
Clinical Info |
This panel is used for the rapid assessment of solid tumor molecular profiles to enable informed treatment decisions. This 161-gene assay analyzes 87 genes with hotspot mutations, 48 full-length genes, as well as 43 genes with focal CNV gains and 51 fusion driver genes. |
Specimen Sources |
Misc |
Specimen Types |
Tissue |
Specimen Volume |
15 Unstained 5-μm FFPE slide and 1 H&E slide |
Container |
Slide |
Collection Instructions |
Container/Tube; Unstained slides Specimen: 15 unstained 5-μm FFPE (unbaked), accompanied with one H&E slide for macrodissection are required. Circled tumor area and noted tumor content on the H&E slide are REQUIRED. |
Transport Instructions |
Room Temperature |
Specimen Stability |
Room Temperature |
Methodology |
Next Generation Sequencing (NGS) on the Genexus System |
Days Performed |
Monday - Friday |
Performing Laboratories |
Northwell Health Labs |
CPT |
81455,88381,G0452 |
PDM |
248472 |
Results |
|
Result InterpretationSee Report This NGS assay is qualitative and is not intended to detect minimal residual disease or for the detection of germline mutations. The assay will detect SNVs and InDels with a variant allele frequency (VAF) greater than 5% but has limited detection of VAFs between 3% and 5%. Copy number gains below 5 will not be detected, particularly in samples with tumor content below 50%. In addition, large insertions or deletions, or mutations in regions with low sequencing coverage or repetitive sequences might not be detected. Therefore, a negative result does not rule out the presence of mutations; thus, clinical, morphological, and immunophenotypic data should always be considered in conjunction with the genomic findings from this assay. |
|
Forms |
|
